{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:04:09Z","timestamp":1789473849294,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Epidemiology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.annepidem.2025.09.003","type":"journal-article","created":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:23:50Z","timestamp":1757859830000},"page":"9-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Artificial intelligence and natural language processing of patient narratives to evaluate semaglutide for weight loss"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0581-7808","authenticated-orcid":false,"given":"Akshaya Srikanth","family":"Bhagavathula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annepidem.2025.09.003_bib1","series-title":"StatPearls [Internet]","article-title":"Semaglutide","author":"Kommu","year":"2025"},{"key":"10.1016\/j.annepidem.2025.09.003_bib2","series-title":"FDA approves new drug treatment for chronic weight management, first since 2014 [Internet]","author":"U.S. Food and Drug Administration","year":"2021"},{"issue":"10","key":"10.1016\/j.annepidem.2025.09.003_bib3","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.annepidem.2025.09.003_bib4","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1111\/dom.15911","article-title":"Semaglutide use in people with obesity and type 2 diabetes from real-world utilization data: an analysis of the all of US program","volume":"26","author":"Mayer","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.annepidem.2025.09.003_bib5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/00325481.2021.1971461","article-title":"Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"133","author":"Campos","year":"2021","journal-title":"Post Med"},{"issue":"8","key":"10.1016\/j.annepidem.2025.09.003_bib6","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s40618-022-01799-2","article-title":"Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients","volume":"45","author":"Marzullo","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"15","key":"10.1016\/j.annepidem.2025.09.003_bib7","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.3390\/nu16152545","article-title":"Real-world evaluation of once-weekly subcutaneous semaglutide in patients with type 2 diabetes mellitus in Spain (SEMA-RW study)","volume":"16","author":"Caballero Mateos","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.annepidem.2025.09.003_bib8","doi-asserted-by":"crossref","DOI":"10.1007\/s00210-025-04403-5","article-title":"Misrepresentation of semaglutide in social media","author":"Propfe","year":"2025","journal-title":"Naunyn Schmiede Arch Pharm"},{"key":"10.1016\/j.annepidem.2025.09.003_bib9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s44263-024-00095-w","article-title":"Sweetening the deal: an infodemiological study of worldwide interest in semaglutide using google trends extended for health application programming interface","volume":"2","author":"Raubenheimer","year":"2024","journal-title":"BMC Glob Public Health"},{"issue":"1","key":"10.1016\/j.annepidem.2025.09.003_bib10","first-page":"5","article-title":"Social media as pharmacovigilance: the potential for patient reports to inform clinical research on glucagon-like peptide 1 (GLP-1) receptor agonists for substance use disorders","volume":"85","author":"Bremmer","year":"2024","journal-title":"J Stud Alcohol Drugs"},{"issue":"10","key":"10.1016\/j.annepidem.2025.09.003_bib11","doi-asserted-by":"crossref","DOI":"10.2196\/24336","article-title":"Areas of interest and attitudes toward antiobesity drugs: thematic and quantitative analysis using twitter","volume":"23","author":"Alvarez-Mon","year":"2021","journal-title":"J Med Internet Res"},{"issue":"1","key":"10.1016\/j.annepidem.2025.09.003_bib12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/asj\/sjad211","article-title":"Public interest in the off-label use of glucagon-like peptide 1 agonists (ozempic) for cosmetic weight loss: a google trends analysis","volume":"44","author":"Han","year":"2023","journal-title":"Aesthet Surg J"},{"issue":"14","key":"10.1016\/j.annepidem.2025.09.003_bib13","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.annepidem.2025.09.003_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.31982","article-title":"Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity","volume":"5","author":"Ghusn","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.annepidem.2025.09.003_bib15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s43856-024-00566-z","article-title":"Using large language models to assess public perceptions around glucagon-like peptide-1 receptor agonists on social media","volume":"4","author":"Somani","year":"2024","journal-title":"Commun Med"},{"key":"10.1016\/j.annepidem.2025.09.003_bib16","article-title":"Ozempic (glucagon-like peptide 1 receptor agonist) in social media posts: unveiling user perspectives through reddit topic modeling","volume":"4","author":"Fong","year":"2024","journal-title":"Emerg Trends Drugs Addict Health"},{"key":"10.1016\/j.annepidem.2025.09.003_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1382814","article-title":"Semaglutide for weight loss: unanswered questions","volume":"15","author":"Tzoulis","year":"2024","journal-title":"Front Endocrinol"},{"issue":"9_Part_2","key":"10.1016\/j.annepidem.2025.09.003_bib18","article-title":"Trends in glucagon-like peptide-1 receptor agonist social media posts using artificial intelligence","volume":"3","author":"Javaid","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.annepidem.2025.09.003_bib19","article-title":"Utilizing AI and social media analytics to discover adverse side effects of GLP-1 receptor agonists","author":"Bartal","year":"2024","journal-title":"arXiv prepr"},{"issue":"2","key":"10.1016\/j.annepidem.2025.09.003_bib20","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/oby.23622","article-title":"Real-world weight-loss effectiveness of glucagon-like peptide-1 agonists among patients with type 2 diabetes: a retrospective cohort study","volume":"31","author":"White","year":"2023","journal-title":"Obesity"},{"key":"10.1016\/j.annepidem.2025.09.003_bib21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/B978-0-12-823337-5.00006-8","article-title":"Chapter 6 \u2013 other key concepts in artificial intelligence","author":"Chang","year":"2020","journal-title":"Intell Based Med"},{"key":"10.1016\/j.annepidem.2025.09.003_bib22","article-title":"Integrating deep learning with machine learning: technological approaches, methodologies, applications, opportunities, and challenges","author":"Rana","year":"2024","journal-title":"SSRN Electron J"}],"container-title":["Annals of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1047279725002571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1047279725002571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T03:59:24Z","timestamp":1764043164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1047279725002571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":22,"alternative-id":["S1047279725002571"],"URL":"https:\/\/doi.org\/10.1016\/j.annepidem.2025.09.003","relation":{},"ISSN":["1047-2797"],"issn-type":[{"value":"1047-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Artificial intelligence and natural language processing of patient narratives to evaluate semaglutide for weight loss","name":"articletitle","label":"Article Title"},{"value":"Annals of Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annepidem.2025.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}